Anti-PD-1 and Anti-CD30 Antibody Conjugate Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for combination therapies that effectively target immune cells involved in cancer pathogenesis, such as T regulatory cells, while maintaining an acceptable safety profile and enhancing antitumor immune responses.
Innovation Solution
Administering a combination of an anti-PD-1 antibody and an anti-CD30 antibody-drug conjugate to patients with solid tumors, where the antibodies or their antigen-binding fragments specifically target PD-1 and CD30, respectively, to modulate immune responses and inhibit tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors are used to enhance anti-tumor immune responses, then immune response enhancement is improved, but tumor resistance develops over time
Solution Approach 1:
The patent combines two different therapeutic mechanisms: checkpoint inhibition (anti-PD-1 antibody) and targeted cytotoxic therapy (anti-CD30 antibody-drug conjugate). This combination merges immune system activation with direct tumor cell killing, addressing both the initial treatment response and the development of resistance over time by attacking the tumor through multiple pathways simultaneously
2Reliability
If T regulatory cells are targeted to enhance anti-tumor immunity, then immune suppression is reduced, but selectivity between tumor and normal tissue must be maintained
Solution Approach 1:
The patent employs an antibody-drug conjugate that provides localized cytotoxic action. The anti-CD30 antibody component ensures that the toxic payload is delivered specifically to CD30-expressing cells (such as T regulatory cells in the tumor microenvironment and CD30+ tumor cells), while the linker maintains stability in circulation and only releases the cytotoxic agent upon binding to the target antigen, thereby achieving local quality control that spares normal tissues
Data Source
AI summary
The invention provides an anti-PD-1 antibody and an antibody-drug conjugate that binds to CD30 and their use in methods of treating solid tumors. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to CD30 for use in treating solid tumors.